These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 39168104)

  • 1. Soluble Tim-3 serves as a tumor prognostic marker and therapeutic target for CD8
    Chen C; Zhao F; Peng J; Zhao D; Xu L; Li H; Ma S; Peng X; Sheng X; Sun Y; Wang T; Dong H; Ding Y; Wu Z; Liang X; Gao L; Wang H; Ma C; Li C
    Cell Rep Med; 2024 Aug; 5(8):101686. PubMed ID: 39168104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR mutations induce the suppression of CD8
    Huang H; Zhu X; Yu Y; Li Z; Yang Y; Xia L; Lu S
    J Transl Med; 2024 Jul; 22(1):653. PubMed ID: 39004699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer.
    Kim CG; Kim G; Kim KH; Park S; Shin S; Yeo D; Shim HS; Yoon HI; Park SY; Ha SJ; Kim HR
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34907028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epithelium/imcDC2 axis facilitates the resistance of neoadjuvant anti-PD-1 in human NSCLC.
    Chen Y; Shao Z; Hao Z; Xin Z; Chen X; Huang L; Chen D; Lin M; Liu Q; Xu X; Li J; Wu D; Yan J; Chai Y; Wu P
    J Immunother Cancer; 2024 Aug; 12(8):. PubMed ID: 39134346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blocking Tim-3 or/and PD-1 reverses dysfunction of tumor-infiltrating lymphocytes in HBV-related hepatocellular carcinoma.
    Liu F; Zeng G; Zhou S; He X; Sun N; Zhu X; Hu A
    Bull Cancer; 2018 May; 105(5):493-501. PubMed ID: 29576222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-1 blockade-unresponsive human tumor-infiltrating CD8
    Kim KH; Kim HK; Kim HD; Kim CG; Lee H; Han JW; Choi SJ; Jeong S; Jeon M; Kim H; Koh J; Ku BM; Park SH; Ahn MJ; Shin EC
    Cell Mol Immunol; 2021 Feb; 18(2):385-397. PubMed ID: 32332901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8
    Peng DH; Rodriguez BL; Diao L; Chen L; Wang J; Byers LA; Wei Y; Chapman HA; Yamauchi M; Behrens C; Raso G; Soto LMS; Cuentes ERP; Wistuba II; Kurie JM; Gibbons DL
    Nat Commun; 2020 Sep; 11(1):4520. PubMed ID: 32908154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.
    Redin E; Garmendia I; Lozano T; Serrano D; Senent Y; Redrado M; Villalba M; De Andrea CE; Exposito F; Ajona D; Ortiz-Espinosa S; Remirez A; Bertolo C; Sainz C; Garcia-Pedrero J; Pio R; Lasarte J; Agorreta J; Montuenga LM; Calvo A
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33658304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blockade of PD-1 and TIM-3 immune checkpoints fails to restore the function of exhausted CD8
    Rezazadeh H; Astaneh M; Tehrani M; Hossein-Nataj H; Zaboli E; Shekarriz R; Asgarian-Omran H
    Immunol Res; 2020 Oct; 68(5):269-279. PubMed ID: 32710227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble T cell immunoglobulin mucin domain 3 is shed from CD8+ T cells by the sheddase ADAM10, is increased in plasma during untreated HIV infection, and correlates with HIV disease progression.
    Clayton KL; Douglas-Vail MB; Nur-ur Rahman AK; Medcalf KE; Xie IY; Chew GM; Tandon R; Lanteri MC; Norris PJ; Deeks SG; Ndhlovu LC; Ostrowski MA
    J Virol; 2015 Apr; 89(7):3723-36. PubMed ID: 25609823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis.
    Datar I; Sanmamed MF; Wang J; Henick BS; Choi J; Badri T; Dong W; Mani N; Toki M; Mejías LD; Lozano MD; Perez-Gracia JL; Velcheti V; Hellmann MD; Gainor JF; McEachern K; Jenkins D; Syrigos K; Politi K; Gettinger S; Rimm DL; Herbst RS; Melero I; Chen L; Schalper KA
    Clin Cancer Res; 2019 Aug; 25(15):4663-4673. PubMed ID: 31053602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer.
    Kim K; Park S; Park SY; Kim G; Park SM; Cho JW; Kim DH; Park YM; Koh YW; Kim HR; Ha SJ; Lee I
    Genome Med; 2020 Feb; 12(1):22. PubMed ID: 32111241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Up-regulation of TIM-3 on CD4+ tumor infiltrating lymphocytes predicts poor prognosis in human non-small-cell lung cancer].
    Ji P; Chen D; Bian J; Xia R; Song X; Wen W; Zhang X; Zhu Y
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2015 Jun; 31(6):808-11. PubMed ID: 26062425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting PD-1 and Tim-3 Pathways to Reverse CD8 T-Cell Exhaustion and Enhance Ex Vivo T-Cell Responses to Autologous Dendritic/Tumor Vaccines.
    Liu J; Zhang S; Hu Y; Yang Z; Li J; Liu X; Deng L; Wang Y; Zhang X; Jiang T; Lu X
    J Immunother; 2016 May; 39(4):171-80. PubMed ID: 27070448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting STAT3 Abrogates Tim-3 Upregulation of Adaptive Resistance to PD-1 Blockade on Regulatory T Cells of Melanoma.
    Huang L; Xu Y; Fang J; Liu W; Chen J; Liu Z; Xu Q
    Front Immunol; 2021; 12():654749. PubMed ID: 33936081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1
    Kurtulus S; Madi A; Escobar G; Klapholz M; Nyman J; Christian E; Pawlak M; Dionne D; Xia J; Rozenblatt-Rosen O; Kuchroo VK; Regev A; Anderson AC
    Immunity; 2019 Jan; 50(1):181-194.e6. PubMed ID: 30635236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune-Checkpoint Blockade Opposes CD8
    Pfannenstiel LW; Diaz-Montero CM; Tian YF; Scharpf J; Ko JS; Gastman BR
    Cancer Immunol Res; 2019 Mar; 7(3):510-525. PubMed ID: 30728151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of TIM-3 expression and its prognostic value in patients with surgically resected lung adenocarcinoma.
    Su H; Xie H; Dai C; Ren Y; She Y; Xu L; Chen D; Xie D; Zhang L; Jiang G; Chen C
    Lung Cancer; 2018 Jul; 121():18-24. PubMed ID: 29858021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tetrandrine activates STING/TBK1/IRF3 pathway to potentiate anti-PD-1 immunotherapy efficacy in non-small cell lung cancer.
    Tan Y; Zhu Q; Yang M; Yang F; Zeng Q; Jiang Z; Li D
    Pharmacol Res; 2024 Sep; 207():107314. PubMed ID: 39059614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A combined model of serum neutrophil extracellular traps, CD8
    Guo J; Shu T; Zhang H; Huang N; Ren J; Lin L; Wu J; Wang Y; Huang Z; Bin J; Liao Y; Shi M; Liao W; Huang N
    FEBS J; 2024 Aug; 291(15):3403-3416. PubMed ID: 38661680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.